VBI Vaccines Inc. (NASDAQ:VBIV) Expected to Announce Earnings of -$0.08 Per Share

Analysts expect VBI Vaccines Inc. (NASDAQ:VBIVGet Rating) to post earnings of ($0.08) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for VBI Vaccines’ earnings. VBI Vaccines reported earnings of ($0.07) per share during the same quarter last year, which indicates a negative year over year growth rate of 14.3%. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that VBI Vaccines will report full year earnings of ($0.31) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.29). For the next financial year, analysts forecast that the firm will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.29) to ($0.16). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow VBI Vaccines.

VBI Vaccines (NASDAQ:VBIVGet Rating) last issued its quarterly earnings data on Monday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). VBI Vaccines had a negative net margin of 11,054.36% and a negative return on equity of 42.79%. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.14 million.

VBIV has been the topic of several analyst reports. Jefferies Financial Group began coverage on shares of VBI Vaccines in a research note on Thursday, December 30th. They set a “buy” rating and a $6.00 price target on the stock. Zacks Investment Research upgraded shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research report on Wednesday, April 20th. Finally, Raymond James dropped their price objective on VBI Vaccines from $9.00 to $6.00 and set a “strong-buy” rating for the company in a report on Tuesday, March 8th.

NASDAQ:VBIV opened at $1.35 on Monday. The company has a quick ratio of 3.92, a current ratio of 4.00 and a debt-to-equity ratio of 0.20. The firm has a market cap of $347.36 million, a P/E ratio of -5.00 and a beta of 1.97. The business’s 50-day moving average price is $1.53 and its 200 day moving average price is $2.13. VBI Vaccines has a 52-week low of $1.21 and a 52-week high of $4.31.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Walleye Capital LLC increased its holdings in VBI Vaccines by 48.2% during the 4th quarter. Walleye Capital LLC now owns 27,011 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 8,783 shares during the period. BlackRock Inc. grew its stake in shares of VBI Vaccines by 3.6% in the fourth quarter. BlackRock Inc. now owns 13,269,221 shares of the biopharmaceutical company’s stock worth $31,049,000 after acquiring an additional 462,785 shares during the last quarter. Wells Fargo & Company MN raised its holdings in VBI Vaccines by 1,934.7% in the 4th quarter. Wells Fargo & Company MN now owns 113,697 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 108,109 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of VBI Vaccines by 243.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,153,567 shares of the biopharmaceutical company’s stock valued at $2,699,000 after buying an additional 818,173 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of VBI Vaccines during the 4th quarter valued at about $126,000. Institutional investors and hedge funds own 43.61% of the company’s stock.

About VBI Vaccines (Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Featured Articles

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.